CATALOGO DEI PRODOTTI DELLA RICERCA

TORTORA, GIAMPAOLO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 18.288
EU - Europa 17.799
AS - Asia 13.094
SA - Sud America 1.752
AF - Africa 427
OC - Oceania 44
Continente sconosciuto - Info sul continente non disponibili 30
Totale 51.434
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 17.986
RU - Federazione Russa 6.478
SG - Singapore 5.117
GB - Regno Unito 4.593
CN - Cina 4.296
IT - Italia 1.400
BR - Brasile 1.357
VN - Vietnam 1.104
HK - Hong Kong 1.065
DE - Germania 1.019
FR - Francia 991
IE - Irlanda 973
SE - Svezia 966
FI - Finlandia 699
KR - Corea 465
NG - Nigeria 191
IN - India 181
UA - Ucraina 167
AR - Argentina 151
CA - Canada 139
JP - Giappone 133
NL - Olanda 124
BD - Bangladesh 112
ID - Indonesia 102
TR - Turchia 101
MX - Messico 94
ZA - Sudafrica 84
IQ - Iraq 70
PL - Polonia 65
EC - Ecuador 59
ES - Italia 57
BE - Belgio 55
UZ - Uzbekistan 44
MA - Marocco 43
CO - Colombia 38
SA - Arabia Saudita 36
VE - Venezuela 36
AU - Australia 35
CL - Cile 35
AT - Austria 33
PK - Pakistan 33
EU - Europa 27
PY - Paraguay 27
PH - Filippine 25
CH - Svizzera 24
MY - Malesia 23
PE - Perù 23
IR - Iran 22
KE - Kenya 22
AE - Emirati Arabi Uniti 19
EG - Egitto 18
LT - Lituania 18
JO - Giordania 16
NP - Nepal 16
TN - Tunisia 16
UY - Uruguay 16
AZ - Azerbaigian 15
CR - Costa Rica 15
CZ - Repubblica Ceca 15
AL - Albania 14
RO - Romania 13
IL - Israele 11
KG - Kirghizistan 11
GR - Grecia 10
JM - Giamaica 10
DZ - Algeria 9
KZ - Kazakistan 9
LK - Sri Lanka 9
LV - Lettonia 9
BG - Bulgaria 7
BO - Bolivia 7
HN - Honduras 7
NZ - Nuova Zelanda 7
PT - Portogallo 7
RS - Serbia 7
BJ - Benin 6
BY - Bielorussia 6
EE - Estonia 6
GT - Guatemala 6
HU - Ungheria 6
NO - Norvegia 6
SK - Slovacchia (Repubblica Slovacca) 6
SN - Senegal 6
SY - Repubblica araba siriana 6
TH - Thailandia 6
DK - Danimarca 5
DO - Repubblica Dominicana 5
LB - Libano 5
PA - Panama 5
QA - Qatar 5
AO - Angola 4
BB - Barbados 4
CY - Cipro 4
GA - Gabon 4
KW - Kuwait 4
MK - Macedonia 4
OM - Oman 4
TG - Togo 4
TT - Trinidad e Tobago 4
AM - Armenia 3
Totale 51.355
Salva come PNG Salva come JPEG
Città #
Southend 4.163
Singapore 2.620
Moscow 1.986
Chandler 1.850
Ashburn 1.660
San Jose 1.591
Dallas 1.573
Jacksonville 1.440
Woodbridge 1.406
Hong Kong 1.050
Ann Arbor 1.008
Dublin 967
Beijing 734
The Dalles 711
Verona 675
Houston 613
Lawrence 396
Princeton 396
Wilmington 379
Los Angeles 345
Ho Chi Minh City 339
Jinan 322
New York 298
Nanjing 279
Shenyang 260
Hanoi 225
Tianjin 193
Abuja 190
Munich 189
Hebei 166
Buffalo 165
São Paulo 158
Changsha 136
Redondo Beach 131
Helsinki 117
Tokyo 117
Santa Clara 113
Nanchang 107
Columbus 100
Zhengzhou 97
Haikou 93
Guangzhou 90
Milan 89
Ningbo 88
Hangzhou 83
Sindelfingen 83
Dong Ket 78
Jiaxing 75
London 68
Orem 67
Turku 67
Council Bluffs 66
Frankfurt am Main 64
Taizhou 60
Seoul 59
Brooklyn 58
Jakarta 58
Montreal 58
Redwood City 58
San Francisco 57
Taiyuan 57
Norwalk 55
Brussels 53
Chennai 53
Chicago 53
Warsaw 53
Denver 52
Johannesburg 48
Stockholm 48
Boardman 47
Seattle 46
Amsterdam 43
Lanzhou 43
Bologna 41
Mexico City 40
Fuzhou 39
Lancaster 38
Tashkent 38
Atlanta 37
Da Nang 37
Rio de Janeiro 36
Haiphong 35
Phoenix 35
Falls Church 34
Dearborn 33
Baghdad 31
Toronto 31
Biên Hòa 30
Redmond 29
Boston 28
Campinas 28
Kent 28
Dongguan 27
Manchester 27
Belo Horizonte 26
Washington 25
New Delhi 24
Nuremberg 24
Rome 24
Ankara 23
Totale 32.183
Salva come PNG Salva come JPEG
Nome #
An FGFR3 autocrine loop sustains acquired resistance to trastuzumab in gastric cancer patients 315
A clinical-biological risk stratification model for resected gastric cancer: prognostic impact of Her2, Fhit, and APC expression status 285
A circulating TH2 cytokines profile predicts survival in patients with resectable pancreatic adenocarcinoma 281
Whole-genome landscape of pancreatic neuroendocrine tumours 280
Can histogram analysis of MR images predict aggressiveness in pancreatic neuroendocrine tumors? 255
Combined inhibition of IL1, CXCR1/2, and TGFβ signaling pathways modulates in-vivo resistance to anti-VEGF treatment 255
Genomic analyses identify molecular subtypes of pancreatic cancer 251
Acquired hemophagocytic syndrome in a patient with synovial sarcoma: a case report 247
ALK gene copy number in lung cancer: Unspecific polyploidy versus specific amplification visible as double minutes 247
Ampulla of Vater Carcinoma: Sequencing Analysis Identifies TP53 Status as a Novel Independent Prognostic Factor and Potentially Actionable ERBB, PI3K, and WNT Pathways Gene Mutations 244
True 3q Chromosomal Amplification in Squamous Cell Lung Carcinoma by FISH and aCGH Molecular Analysis: Impact on Targeted Drugs 241
ALK/EML4 Fusion Gene May Be Found in Pure Squamous Carcinoma of the Lung 239
BRCA somatic and germline mutation detection in paraffin embedded ovarian cancers by next-generation sequencing 238
Adipocytes sustain pancreatic cancer progression through a non-canonical WNT paracrine network inducing ROR2 nuclear shuttling 232
Molecular typing of lung adenocarcinoma on cytological samples using a multigene next generation sequencing panel 230
Cathepsin K expression in castration-resistant prostate carcinoma: a therapeutical target for patients at risk for bone metastases 229
High-throughput mutation profiling identifies novel molecular dysregulation in high-grade intraepithelial neoplasia and early gastric cancers 225
Monosomy of chromosome 17 in breast cancer during interpretation of HER2 gene amplification 219
Perfusion Changes in Liver Metastases (LM) from Pancreatic Neuroendocrine Tumors (PanNETs) during Everolimus (E) Treatment: Update of Perfusion CT (P-CT) Study 218
Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups 214
Magnitude of PD-1, PD-L1 and T Lymphocyte Expression on Tissue from Castration-Resistant Prostate Adenocarcinoma: An Exploratory Analysis 214
An overview of angiogenesis inhibitors in Phase II studies for non-small-cell lung cancer 212
Adenocarcinoma of the paraurethral glands: a case report 209
The incidence and relative risk of pulmonary toxicity in patients treated with anti-PD1/PD-L1 therapy for solid tumors: a meta-analysis of current studies 209
Tumor thrombosis: a peculiar finding associated with pancreatic neuroendocrine neoplasms. A pictorial essay 209
Prognostic impact of proliferation for resected early stage 'pure' invasive lobular breast cancer: Cut-off analysis of Ki67 according to histology and clinical validation 207
Corrigendum: Whole-genome landscape of pancreatic neuroendocrine tumours 203
Angiopoietin-Like Proteins in Angiogenesis, Inflammation and Cancer 201
Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers 200
Next-generation repeat-free FISH probes for DNA amplification in glioblastoma in vivo: Improving patient selection to MDM2-targeted inhibitors 200
The Tumor Entity Denominated "clear cell-papillary renal cell carcinoma" According to the WHO 2016 new Classification, have the Clinical Characters of a Renal Cell Adenoma as does Harbor a Benign Outcome 199
Addressing the best treatment for non-clear cell renal cell carcinoma: A meta-analysis of randomised clinical trials comparing VEGFR-TKis versus mTORi-targeted therapies 198
The Cardiovascular Toxicity of Abiraterone and Enzalutamide in Prostate Cancer 198
Impact of neoadjuvant single or dual HER2 inhibition and chemotherapy backbone upon pathological complete response in operable and locally advanced breast cancer: Sensitivity analysis of randomized trials 196
Tumor Perfusion Changes During Everolimus (E) Treatment: Preliminary Results from Perfusion-CT (P-CT) Study 196
Comparison Between Prognostic Classifications in De Novo Metastatic Hormone Sensitive Prostate Cancer 196
Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of Ki67 assay according to histology: prognostic relevance for resected early stage 'pure' and 'mixed' lobular breast cancer 195
Reprofiling Metastatic Samples for Chromosome 9p and 14q Aberrations as a Strategy to Overcome Tumor Heterogeneity in Clear-cell Renal Cell Carcinoma 194
Adjuvant Chemotherapy For Resected Non-Small-Cell Lung Cancer: Future Perspectives For Clinical Research 194
Methods to identify molecular expression of mTOR pathway: a rationale approach to stratify patients affected by clear cell renal cell carcinoma for more likely response to mTOR inhibitors. 192
Investigating BRCA Mutations: A Breakthrough in Precision Medicine of Castration-Resistant Prostate Cancer 191
Perfusion CT Changes in Liver Metastases from Pancreatic Neuroendocrine Tumors During Everolimus Treatment 191
Homeobox B9 Mediates Resistance to Anti-VEGF Therapy in Colorectal Cancer Patients 191
Reporting tumor molecular heterogeneity in histopathological diagnosis 190
Pancreatic neuroendocrine neoplasms: Magnetic resonance imaging features according to grade and stage 190
Emerging pathways and future targets for the molecular therapy of pancreatic cancer. 189
ESGAR 2016 Book of Abstracts 189
FGFR-1 amplification in metastatic lymph-nodal and haematogenous lobular breast carcinoma. 188
Role of Combined Ga-68-DOTATOC and F-18-FDG Positron Emission Tomography/Computed Tomography in the Diagnostic Workup of Pancreas Neuroendocrine Tumors Implications for Managing Surgical Decisions 188
Current Strategies to Overcome Resistance to ALK-Inhibitor Agents 187
Current and developing therapies for the treatment of non-small cell lung cancer with ALK abnormalities: update and perspectives for clinical practice 187
Evaluation of cell-free DNA as a biomarker for pancreatic malignancies 187
Prognostic impact of early nutritional support in patients affected by locally advanced and metastatic pancreatic ductal adenocarcinoma undergoing chemotherapy 187
De novo metastatic castration sensitive prostate cancer: State of art and future perspectives 186
Adjuvant treatment for resected renal cell carcinoma: are all strategies equally negative? Potential implications for trial design with targeted agents. 186
The identification of a small but significant subset of patients still targetable with anti-HER2 inhibitors when affected by triple negative breast carcinoma 186
Renal cell carcinoma in one year: Going inside the news of 2017 - A report of the main advances in RCC cancer research 185
An angiopoietin-like protein 2 autocrine signaling promotes EMT during pancreatic ductal carcinogenesis 185
Addressing the expected survival benefit for clinical trial design in metastatic castration-resistant prostate cancer: Sensitivity analysis of randomized trials 185
Targeting Met and VEGFR Axis in Metastatic Castration-Resistant Prostate Cancer: 'Game Over'? 185
Pancreatic Cancer and Obesity: Molecular Mechanisms of Cell Transformation and Chemoresistance 184
Balancing activity and tolerability of neoadjuvant paclitaxel- and docetaxel-based chemotherapy for HER2-positive early stage breast cancer: Sensitivity analysis of randomized trials 184
Antitumor activity of ZD6126, a novel vascular-targeting agent, is enhanced when combined with ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, and potentiates the effects of radiation in a human non-small cell lung cancer xenograft model. 183
A selective cyclooxygenase-2 inhibitor combined with the epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) ZD1839 ('Iressa') and protein kinase A antisense causes cooperative tumor growth inhibition after oral administration 183
Adjuvant treatment for resected renal cell carcinoma: are all strategies equally negative? Potential implications for trial design with targeted agents. 183
A novel modified CpG agonist of TLR-9 inhibits EGF receptor signalling and synergistically enhances antitumor activity of cetuximab and irinotecan eradicating colon cancer xenografts 182
Wide spetcrum mutational analysis of metastatic renal cell cancer: a retrospective next generation sequencing approach 182
Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas 181
Molecular heterogeneity assessment by next-generation sequencing and response to gefitinib of EGFR mutant advanced lung adenocarcinoma 179
The coming of ramucirumab in the landscape of anti-angiogenic drugs: potential clinical and translational perspectives 179
Organoid-Transplant Model Systems to Study the Effects of Obesity on the Pancreatic Carcinogenesis in vivo 179
AR-V7 and prostate cancer: The watershed for treatment selection? 178
Neoadjuvant strategies for triple negative breast cancer: 'state-of-the-art' and future perspectives 177
Gene expression profiling of lung atypical carcinoids and large cell neuroendocrine carcinomas identifies three transcriptomic subtypes with specific genomic alterations 177
HER2/neu Gene Determination in Women Screened for Breast Carcinoma: How Screening Programs Reduce the Skyrocketing Cost of Targeted Therapy 176
Advances towards the design and development of personalized non-small-cell lung cancer drug therapy. 175
The development of PARP as a successful target for cancer therapy 175
Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Heat Shock Protein 90 Overexpression, Ki67 Proliferative Index, and Topoisomerase II-α Co-amplification as Predictors of Pathologic Complete Response to Neoadjuvant Chemotherapy With Trastuzumab and Docetaxel 175
Hypermutation In Pancreatic Cancer 174
Prognostic Value of Beta-Tubulin-3 and c-Myc in Muscle Invasive Urothelial Carcinoma of the Bladder 174
Adjuvant therapy for resected early-stage small-cell lung cancer: is now time to rethink about that? 174
Immunotherapy versus standard of care in metastatic renal cell carcinoma. A systematic review and meta-analysis 173
A propensity score analysis exploring the impact of adjuvant chemotherapy (aCT) in a multi-center series of resected early stage pure invasive lobular breast carcinoma (ILC) 173
Preliminary results of PRINCiPe (predictors of resistance to immunotherapy with nivolumab [NIV]) study in advanced pretreated non-small cell lung cancer (APNSCLC), investigating the role of an immune genomic signature (IGS) including JAK2, JAK3, PIAS4, PTPN2, STAT3, IFNAR2 alterations 172
Prognostication and response assessment in liver and pancreatic tumors: The new imaging 172
Lung neuroendocrine tumours: deep sequencing of the four WHO histotypes reveals chromatin remodelling genes as major players and a prognostic role for TERT, RB1, MEN1 and KMT2D 171
TAK1-regulated expression of BIRC3 predicts resistance to preoperative chemoradiotherapy in oesophageal adenocarcinoma patients 170
Tumor seeding after percutaneous US-guided FNA of solid pancreatic neoplasms 170
8-Chloro-cAMP inhibits transforming growth factor alpha transformation of mammary epithelial cells by restoration of the normal mRNA patterns for cAMP-dependent protein kinase regulatory subunit isoforms which show disruption upon transformation. 170
Tubulin inhibitors in non-small cell lung cancer: looking back and forward 169
2015 and human cancer: back to overall survival 168
AGENTI BIOLOGICI e CHEMIOTERAPICI: INTEGRAZIONE 165
Molecular Pathology of Pancreatic Cancer: from bench-to-bedside translation. 164
Predictive and Prognostic Role of Tumor-Infiltrating Lymphocytes for Early Breast Cancer According to Disease Subtypes: Sensitivity Analysis of Randomized Trials in Adjuvant and Neoadjuvant Setting 164
Clinical implication of changes in body composition and weight in patients with early-stage and metastatic breast cancer 164
Do immune checkpoint inhibitors need new studies methodology? 163
The route to personalized medicine in bladder cancer: where do we stand? 162
Pancreatic neuroendocrine neoplasms: MRI features and correlation with their histological grade 162
Metabolic phenotype of bladder cancer 162
Tumor Perfusion Changes During Everolimus (E) Treatment: Preliminary Results from Perfusion-CT (P-CT) Study 161
Totale 19.649
Salva come PNG Salva come JPEG
Categoria #
all - tutte 167.774
article - articoli 152.431
book - libri 457
conference - conferenze 11.342
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 3.544
Totale 335.548
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021570 0 0 0 0 0 0 0 0 0 76 306 188
2021/20222.725 202 780 17 208 94 46 41 175 109 61 198 794
2022/20235.491 472 505 554 860 534 1.409 54 323 582 36 118 44
2023/20242.404 103 200 180 202 381 380 51 232 45 125 353 152
2024/20257.291 400 446 238 1.317 252 196 248 310 1.242 490 585 1.567
2025/202620.350 1.660 1.073 1.729 3.557 5.247 1.289 2.014 1.103 1.671 1.007 0 0
Totale 51.843